The financial structure of the deal includes an initial payment of $8 million upon closing, with an additional $3 million tied to technology transfer and commercial milestones achievable over the next 18 months. While the agreement marks a significant shift in the company's portfolio, the transaction is not slated to finalize until the second half of 2026.

By shedding SimpliDerm, Elutia secures non-dilutive capital to accelerate the development of NXT-41x. The company views this next-generation product as a primary growth driver for the plastic and reconstructive surgery sector, targeting a U.S. market segment estimated at $1.5 billion. Elutia anticipates a focused commercial launch for the new biomatrix in 2027.